Health Care · Pharmaceutical Preparations

VTRS Viatris SEC Filings & Insider Trading Activity 2026

company
CIK 179204485 filings
S&P 500

VTRS at a glance

Viatris (VTRS, SEC CIK 1792044) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 17, 2026 and Form 4 insider filings as recently as October 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Viatris (VTRS) reported revenue of $14.3 billion (down 3.0% from FY2024) and a net loss of $3.5 billion. Diluted EPS was -$3.00.
  • As of September 30, 2026, 49 institutional investment managers tracked by SignalX reported holding Viatris (VTRS) shares worth $8.3 billion in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$14.3B
−3.0% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
49 funds
$8.3B · −1 vs prior quarter
Latest 8-K
Nov 17, 2026
Item 7.01 · Item 2.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Global pharma company delivering generics, branded generics, and innovative medicines to ~1B patients across 165+ countries with 30,000+ employees and 27 manufacturing sites
  • Five positive Phase 3 readouts in 2025: meloxicam acute pain, low-dose estrogen patch (FDA action target July 30, 2026), LYNX-2 night driving (MR-142), VEGA-3 presbyopia (MR-141, FDA action H2 2026), and EFFEXOR Japan GAD
  • EWSR launched 2025: up to ~10% global workforce reduction, $700M–$850M in restructuring charges, targeting $600M–$700M in savings once fully implemented
  • 2025 total revenues $14.30B; returned >$1B to shareholders (~$500M buybacks + $561M dividends) despite divestiture headwinds and Indore FDA warning letter impact
  • Acquired Aculys Pharma (Oct 2025) for Japan-exclusive rights to pitolisant (narcolepsy/sleep apnea) and Spydia® Nasal Spray: sharpest pivot yet toward patent-protected innovative assets in Japan

Risk Factors

  • FDA warning letter & import alert on Indore, India oral dose facility restricting U.S. distribution, with unrecovered revenue impact in FY2025
  • U.S. tariffs on pharmaceutical imports (including API) threatening cost structure; competitors may be disproportionately less affected
  • Top 3 customers ~25% of net sales; limited manufacturing sites plus post-divestiture API supply dependence on single external vendor
  • Inflation Reduction Act (2022) drug price negotiation and most-favored-nation pilot programs risk compressing innovative pipeline product margins
  • Significant indebtedness with refinancing risk at higher rates; $2.94B goodwill impairment charge taken in 2025

Management Discussion & Analysis

  • Revenue $14.30B, down 3% YoY ($439M decline); Indore facility impact ~$370M drag; Greater China only growth segment, +8% to $2.33B
  • Gross margin 35% vs 38%; adjusted gross margin 56% vs 58%; operating loss $(2.66B) vs near-breakeven $10M in 2024, driven by $2.94B goodwill impairment
  • Best segment: Greater China +8% constant currency; worst: JANZ -11% ($152M decline) from government price cuts and Indore impact
  • Operating cash flow $2.32B (up $13M YoY); capex $378.8M; buybacks $500.5M; dividends $561.2M; 2026 capex guided $350M–$450M
  • 2026 restructuring program targets $600M–$700M savings, $700M–$850M pre-tax charges; Nashik plant fire (Feb 2026) adds supply risk; biosimilar non-compete expiry unlocks new revenue opportunity

AI summary of the VTRS 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New acquisition risk: Pacira transaction may fail or face delays due to tender, regulatory, legal and closing conditions
  • Most material update: Pacira integration may underperform, limiting anticipated benefits, synergies and operating efficiencies
  • Regulatory risk: Hart-Scott-Rodino waiting-period expiration required before Pacira offer completion
  • Operational risk: Viatris may fail to retain Pacira talent supporting commercial, market access, medical affairs and R&D capabilities
  • Financial risk: Transaction setbacks could affect cash flows, dividends, share repurchases and stock price

Management Discussion & Analysis

  • Q3 revenue $3.75B vs $3.76B, down $10.4M YoY, essentially flat
  • Gross margin 38% vs 36%; adjusted gross margin approximately 58% vs 56%
  • Best segment Greater China: $702.6M, up 14%; worst Emerging Markets: $529.1M, down 7%
  • Operating cash flow $1.67B through September, up $169.4M; repurchases $150.0M in Q3
  • Nashik disruption: approximately $100M Q4 revenue impact; production expected to resume Q1 2027

AI summary of the VTRS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 17, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Viatris announced consummation of the Merger, marking completion of a material corporate transaction
  • Investors should review Exhibit 99.1 for merger consideration, strategic rationale and expected financial impact

Item 2.01: Completion of Acquisition or Disposition of Assets

  • Viatris completed Pacira acquisition on November 17, 2026, making Pacira a wholly owned subsidiary
  • Offer price $36.50 per share in cash, with 32,929,780 shares tendered, representing 66.46% ownership

Item EX-99.1: Item EX-99.1

  • Viatris completed Pacira acquisition, adding Pacira’s non-opioid pain portfolio to its U.S. innovative medicines business
  • Cash consideration of $36.50 per share, with approximately 32,929,780 shares tendered, representing 66.46% of outstanding shares
Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Viatris reported financial results for the period ended September 30, 2026
  • Press release issued November 5, 2026, with detailed results in Exhibit 99.1

Item 8.01: Other Events

  • Conference call and live webcast at 8:30 a.m. ET to review Viatris financial results
  • Results cover the period ended September 30, 2026

Item EX-99.1: Item EX-99.1

  • Q3 revenue $3.75B was flat, while adjusted EBITDA rose 4% to $1.20B and adjusted EPS increased 6% to $0.71
  • U.S. GAAP net loss widened to $325M, driven primarily by higher income taxes on losses with limited realizable tax benefits
Filed Oct 8, 2026Full analysis →

Item 8.01: Other Events

  • Viatris and Pacira announced a merger agreement on October 8, 2026, initiating a proposed acquisition subject to closing conditions
  • Tender offer has not commenced, with Viatris expected to file Schedule TO and Pacira Schedule 14D-9

Item 1.01: Entry into a Material Definitive Agreement

  • Viatris agreed to acquire Pacira for $36.50 per share in cash through a tender offer
  • Offer requires more than 50% of Pacira shares tendered, with no financing condition

Item EX-99.2: Item EX-99.2

  • Viatris plans to acquire Pacira BioSciences, signaling expansion into specialty pharmaceuticals

Item EX-99.1: Item EX-99.1

  • Viatris agreed to acquire Pacira for $36.50 per share in cash, valuing equity at $1.65 billion
  • Pacira generated $746 million revenue and $177 million adjusted EBITDA for the twelve months ended June 30, 2026

AI summaries of VTRS 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for VTRS

Don't miss the next VTRS filing

  • Alerts as it files. A push when VTRS files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut VTRS, by share count.
  • Ask anything. An AI agent that reads every VTRS filing and answers with sources.

VTRS alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Groothuis Leo FransASep 30, 2026$17.72
SIMMONS DAVID SASep 30, 2026$17.72
Enrietti AndrewMAug 15, 2026-
Enrietti AndrewFAug 15, 2026$16.23
Enrietti AndrewFAug 15, 2026$16.23
Enrietti AndrewMAug 15, 2026-
Enrietti AndrewMAug 15, 2026-
Enrietti AndrewMAug 15, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$14.7B$14.3B
Gross Profit-$5.6B$5.0B
Operating Income-$10.1M-$2.7B
Net Income--$634.2M-$3.5B
Gross Margin-38.3%35.2%
Op. Margin-0.1%-18.7%
Net Margin--4.3%-24.7%
Balance Sheet
Total Assets$47.7B$41.5B$37.2B
Equity$20.5B$18.6B$14.7B
ROE--3.4%-23.9%
Per Share
EPS-$-0.53$-3.00
Cash Flow
Operating CF-$2.3B$2.3B
CapEx-$326.0M$378.8M

Source: XBRL data in Viatris (VTRS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate VTRS share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
VTRS shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202649$8.31B
Q2 202650$9.48B
Q1 202648$7.15B
Q4 202542$6.99B
Q3 202543$5.68B
Q2 202544$4.87B
Q1 202539$3.17B
Q4 202437$4.14B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 352 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

VTRS filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 17, 2026Analysis-
10-QNov 5, 2026Analysis
8-KNov 5, 2026Analysis-
8-KOct 8, 2026Analysis-
4Oct 2, 2026--
4Oct 2, 2026--
4Aug 18, 2026--
8-KAug 6, 2026Analysis-
SC 13GAug 6, 2026-
10-QAug 6, 2026Analysis
8-KJul 1, 2026Analysis-
4Jul 1, 2026--
4Jul 1, 2026--
4Jun 26, 2026--
8-KJun 18, 2026Analysis-
8-KJun 15, 2026Analysis-
8-KMay 15, 2026Analysis
10-QMay 7, 2026Analysis
8-KMay 7, 2026Analysis
8-KMay 4, 2026Analysis-
SC 13GApr 30, 2026-
4Apr 16, 2026--
4Mar 24, 2026--
4Mar 10, 2026--
4Mar 10, 2026--

Related Health Care companies

All Health Care →

VTRS SEC filings: frequently asked questions

Which institutions hold VTRS stock?

As of September 30, 2026, the largest Viatris (VTRS) holders among the 13F filers tracked by SignalX were BlackRock ($1.5 billion), Vanguard Capital Management LLC ($1.3 billion), T. Rowe Price Group ($1.0 billion), Vanguard Portfolio Management LLC ($962.3 million), State Street Corp ($821.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was VTRS's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Viatris (VTRS) reported revenue of $14.3 billion (down 3.0% from FY2024) and a net loss of $3.5 billion. Diluted EPS was -$3.00. The figures come from the XBRL data in the 10-K.

What are the main risks in VTRS's latest 10-K?

In the 10-K filed February 26, 2026, Viatris (VTRS) flagged: FDA warning letter & import alert on Indore, India oral dose facility restricting U.S. distribution, with unrecovered revenue impact in FY2025. U.S. tariffs on pharmaceutical imports (including API) threatening cost structure; competitors may be disproportionately less affected. (AI summary of the Risk Factors section.)

What did VTRS report in its latest 8-K?

Viatris (VTRS) filed an 8-K on November 17, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 2.01 (Completion of Acquisition or Disposition of Assets). Viatris announced consummation of the Merger, marking completion of a material corporate transaction.

What are the latest VTRS SEC filings?

Viatris (VTRS) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 17, 2026 and a Form 4 insider filing on October 2, 2026.

What is VTRS's SEC CIK number?

Viatris (VTRS)'s SEC Central Index Key (CIK) is 1792044. EDGAR lists every VTRS filing under that number.

Ask anything about VTRS

The research agent reads VTRS's filings, financials, insider trades and 13F holders, then answers with sources.